Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1
Zhenzhu SunThe First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, Zhejiang, ChinaWenqiang LuZhejiang University School of Medicine, Hangzhou, ChinaNa LinZhejiang Chinese Medical University, Hangzhou, ChinaHui LinDepartment of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang, ChinaJie ZhangDepartment of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang, ChinaTingjuan NiZhejiang University School of Medicine, Hangzhou, ChinaLiping MengDepartment of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang, ChinaChuanjing ZhangZhejiang University School of Medicine, Hangzhou, ChinaHangyuan GuoThe First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, Zhejiang, China; Department of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang, China. Electronic address: [email protected]
2020en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references